Some studies showed that PHF6 mutations predicted a shorter overall survival in patients with intermediate-risk AML [20], whereas others showed that PHF6 mutations had no prognostic impact when compared with patients with wild-type PHF6 [5]. This evidence concerns the gene PHF6 and acute myeloid leukemia.